Early relapse after rituximab treatment in a patient with seronegative neuromyelitis optica spectrum disorder: a case report

키워드

참고문헌 (9)

1. Jarius S, "Neuromyelitis optica", Nat Rev Dis Primers, 6, pp.85~ (2020)
2. Huang W, "Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders : a systematic review and network meta-analysis", Mult Scler Relat Disord, 35, pp.246~252 (2019)
3. Shi B, "Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder", Mult Scler Relat Disord, 54, pp.103143~ (2021)
4. Jacob A, "Treatment of neuromyelitis optica with rituximab : retrospective analysis of 25 patients", Arch Neurol, 65, pp.1443~1448 (2008)
5. Lindsey JW, "Variable results after rituximab in neuromyelitis optica", J Neurol Sci, 317, pp.103~105 (2012)
6. Perumal JS, "Disease exacerbation after rituximab induction in neuromyelitis optica", Neurol Neuroimmunol Neuroinflamm, 2, pp.e61~ (2015)
7. Wingerchuk DM, "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders", Neurology, 85, pp.177~189 (2015)
8. Maurer MA, "Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination", J Neuroimmunol, 290, pp.49~53 (2016)
9. Gong Q, "Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy", J Immunol, 174, pp.817~826 (2005)

관련 논문AI추천